School of Basic Medical Sciences, Yunnan University of Chinese Medicine, Kunming, China.
The First School of Clinical Medicine, Yunnan University of Chinese Medicine, Kunming, China.
Front Immunol. 2022 Sep 8;13:1007165. doi: 10.3389/fimmu.2022.1007165. eCollection 2022.
Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the joints. Microbial infection is considered a crucial inducer of RA. Alterations in the composition of intestinal bacteria in individuals with preclinical and established RA suggest a vital role of the gut microbiota in immune dysfunction characteristic of RA. However, the mechanisms by which gut dysbiosis contributes to RA are not fully understood. Furthermore, multiple therapies commonly used to treat RA may alter gut microbiota diversity, suggesting that modulating the gut microbiota may help prevent or treat RA. Hence, a better understanding of the changes in the gut microbiota that accompany RA should aid the development of novel therapeutic approaches. This mini-review discusses the impact of gut dysbiosis in the pathogenesis of RA, the selection of gut microbiota-related biomarkers for diagnosing RA, and provides examples of cross-modulation between the gut microbiota and some drugs commonly used to treat RA. Some suggestions and outlooks are also raised, which may help guide future research efforts.
类风湿关节炎(RA)是一种慢性自身免疫性疾病,主要影响关节。微生物感染被认为是 RA 的一个关键诱因。临床前和确诊的 RA 患者的肠道细菌组成发生改变,这表明肠道微生物群在 RA 特征性免疫功能障碍中起着重要作用。然而,肠道菌群失调导致 RA 的机制尚不完全清楚。此外,常用于治疗 RA 的多种疗法可能会改变肠道微生物多样性,这表明调节肠道微生物群可能有助于预防或治疗 RA。因此,更好地了解伴随 RA 发生的肠道微生物群的变化,应该有助于开发新的治疗方法。这篇迷你综述讨论了肠道菌群失调在 RA 发病机制中的作用、用于诊断 RA 的肠道微生物群相关生物标志物的选择,并提供了一些肠道微生物群与一些常用于治疗 RA 的药物之间相互调节的例子。还提出了一些建议和展望,这可能有助于指导未来的研究工作。